Clinical trial
A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
NCT06937203 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- May 9, 2025
- Completion date
- February 28, 2027
- Enrollment
- 150 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.